{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:22:52Z","timestamp":1788870172824,"version":"build-2803163510"},"reference-count":54,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004323","name":"Amylin Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.amjmed.2013.06.010","type":"journal-article","created":{"date-parts":[[2013,8,13]],"date-time":"2013-08-13T23:49:43Z","timestamp":1376437783000},"page":"S21-S27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"S1","title":["Initiating Basal Insulin Therapy in Type 2 Diabetes: Practical Steps to Optimize Glycemic Control"],"prefix":"10.1016","volume":"126","author":[{"given":"Athena","family":"Philis-Tsimikas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2013.06.010_bib1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.diabres.2009.10.007","article-title":"Global estimates of the prevalence of diabetes for 2010 and 2030","volume":"87","author":"Shaw","year":"2010","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.amjmed.2013.06.010_bib2","unstructured":"World Health Organization. Diabetes fact sheet 312 (2011). Available at: http:\/\/www.who.int\/mediacentre\/factsheets\/fs312\/en\/. Accessed April 22, 2013."},{"key":"10.1016\/j.amjmed.2013.06.010_bib3","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2013.06.010_bib4","first-page":"598","article-title":"Glycemic response to newly initiated diabetes therapies","volume":"13","author":"Karter","year":"2007","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.amjmed.2013.06.010_bib5","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/jama.281.21.2005","article-title":"Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group","volume":"281","author":"Turner","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2013.06.010_bib6","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjmed.2013.06.010_bib7","doi-asserted-by":"crossref","first-page":"330","DOI":"10.2337\/diacare.25.2.330","article-title":"UKPDS 57. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57)","volume":"25","author":"Wright","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2013.06.010_bib8","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.amjmed.2013.06.010_bib9","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2337\/diab.44.11.1249","article-title":"U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease","volume":"44","year":"1995","journal-title":"Diabetes"},{"issue":"9131","key":"10.1016\/j.amjmed.2013.06.010_bib10","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2013.06.010_bib11","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1056\/NEJMoa075392","article-title":"Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes","volume":"357","author":"Holman","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl","key":"10.1016\/j.amjmed.2013.06.010_bib12","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.amjmed.2013.06.011","article-title":"Intensifying insulin therapy: what options are available to patients with type 2 diabetes?","volume":"126","author":"Meneghini","year":"2013","journal-title":"Am J Med"},{"issue":"Suppl 1","key":"10.1016\/j.amjmed.2013.06.010_bib13","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2337\/dc13-S011","article-title":"Standards of medical care in diabetes \u2013 2013","volume":"36","author":"American Diabetes Association","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2013.06.010_bib14","doi-asserted-by":"crossref","first-page":"327","DOI":"10.4158\/EP13176.CSUPPL","article-title":"AACE comprehensive diabetes management algorithm 2013","volume":"19","author":"Garber","year":"2013","journal-title":"Endocr Pract"},{"key":"10.1016\/j.amjmed.2013.06.010_bib15","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1111\/j.1464-5491.2007.02279.x","article-title":"Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with Type 2 diabetes: a population-based analysis in the UK","volume":"24","author":"Rubino","year":"2007","journal-title":"Diabet Med"},{"key":"10.1016\/j.amjmed.2013.06.010_bib16","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11606-007-0139-y","article-title":"Delay of insulin addition to oral combination therapy despite inadequate glycemic control: delay of insulin therapy","volume":"22","author":"Nichols","year":"2007","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.amjmed.2013.06.010_bib17","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.2337\/diacare.28.11.2673","article-title":"Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study","volume":"28","author":"Peyrot","year":"2005","journal-title":"Diabetes Care"},{"issue":"Suppl B","key":"10.1016\/j.amjmed.2013.06.010_bib18","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.clinthera.2005.11.020","article-title":"Postprandial glucose regulation: new data and new implications","volume":"27","author":"Leiter","year":"2005","journal-title":"Clin Ther"},{"issue":"Suppl","key":"10.1016\/j.amjmed.2013.06.010_bib19","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.amjmed.2013.06.012","article-title":"Breaking down patient and physician barriers to optimize glycemic control in type 2 diabetes","volume":"126","author":"Ross","year":"2013","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2013.06.010_bib20","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2337\/dc09-1184","article-title":"Barriers to insulin initiation: the translating research into action for diabetes insulin starts project","volume":"33","author":"Karter","year":"2010","journal-title":"Diabetes Care"},{"issue":"164","key":"10.1016\/j.amjmed.2013.06.010_bib21","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1742-1241.2009.02176.x","article-title":"Barriers to insulin initiation and intensification and how to overcome them","author":"Kunt","year":"2009","journal-title":"Int J Clin Pract Suppl"},{"key":"10.1016\/j.amjmed.2013.06.010_bib22","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1464-5491.2005.01501.x","article-title":"Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study","volume":"22","author":"Donnelly","year":"2005","journal-title":"Diabet Med"},{"key":"10.1016\/j.amjmed.2013.06.010_bib23","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.2337\/db08-1084","article-title":"The barrier of hypoglycemia in diabetes","volume":"57","author":"Cryer","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.amjmed.2013.06.010_bib24","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/j.1651-2227.2005.tb01810.x","article-title":"Persistent effects of a pedagogical device targeted at prevention of severe hypoglycaemia: a randomized, controlled study","volume":"94","author":"Nordfeldt","year":"2005","journal-title":"Acta Paediatr"},{"issue":"Suppl 3A","key":"10.1016\/j.amjmed.2013.06.010_bib25","doi-asserted-by":"crossref","first-page":"10S","DOI":"10.1016\/j.amjmed.2003.12.004","article-title":"Basal insulin supplementation in type 2 diabetes; refining the tactics","volume":"116","author":"Rosenstock","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2013.06.010_bib26","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/dmrr.1292","article-title":"Effects of a combination of oral antidiabetes drugs with basal insulin therapy on \u03b2-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes","volume":"28","author":"Mu","year":"2012","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.amjmed.2013.06.010_bib27","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.2337\/dc10-1911","article-title":"Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study","volume":"34","author":"Lucidi","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2013.06.010_bib28","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.2337\/diacare.23.8.1130","article-title":"Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes","volume":"23","author":"Yki-J\u00e4rvinen","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2013.06.010_bib29","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","article-title":"The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients","volume":"26","author":"Riddle","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2013.06.010_bib30","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.2337\/dc05-1365","article-title":"A\u00a026-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes","volume":"29","author":"Hermansen","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2013.06.010_bib31","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.clinthera.2006.10.020","article-title":"Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes","volume":"28","author":"Philis-Tsimikas","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.amjmed.2013.06.010_bib32","doi-asserted-by":"crossref","first-page":"950","DOI":"10.2337\/diacare.28.4.950","article-title":"Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes","volume":"28","author":"Rosenstock","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2013.06.010_bib33","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.diabres.2008.04.007","article-title":"Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis","volume":"81","author":"Monami","year":"2008","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.amjmed.2013.06.010_bib34","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s00125-007-0911-x","article-title":"A\u00a0randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes","volume":"51","author":"Rosenstock","year":"2008","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"10.1016\/j.amjmed.2013.06.010_bib35","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1089\/dia.2010.0251","article-title":"The future of basal insulin supplementation","volume":"13","author":"Simon","year":"2011","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.amjmed.2013.06.010_bib36","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2013.06.010_bib37","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1185\/03007990902840871","article-title":"Once-daily insulin detemir in a cohort of insulin-na\u00efve patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study","volume":"25","author":"Meneghini","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.amjmed.2013.06.010_bib38","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/j.1463-1326.2007.00804.x","article-title":"The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes\u2013results of the randomized, controlled PREDICTIVE 303 study","volume":"9","author":"Meneghini","year":"2007","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.amjmed.2013.06.010_bib39","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1463-1326.2009.01060.x","article-title":"Patient-directed titration for achieving glycemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study","volume":"11","author":"Blonde","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.amjmed.2013.06.010_bib40","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.2337\/diacare.28.5.1245","article-title":"Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia","volume":"28","author":"American Diabetes Association","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2013.06.010_bib41","doi-asserted-by":"crossref","first-page":"78","DOI":"10.2337\/diaclin.23.2.78","article-title":"A\u00a0real-world approach to insulin therapy in clinical practice","volume":"23","author":"Hirsch","year":"2005","journal-title":"Clin Diabetes"},{"key":"10.1016\/j.amjmed.2013.06.010_bib42","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: ongoing review of Avandia (rosiglitazone) and cardiovascular safety. February 2010. Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm201418.htm. Accessed April 22, 2013."},{"key":"10.1016\/j.amjmed.2013.06.010_bib43","unstructured":"US Food and Drug Administration. FDA Drug safety communication: update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer. June 2011. Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm259150.htm. Accessed April 22, 2013."},{"issue":"Suppl","key":"10.1016\/j.amjmed.2013.06.010_bib44","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.amjmed.2013.06.009","article-title":"Options for combination therapy in type 2 diabetes: comparison of ADA\/EASD position statement and AACE\/ACE algorithm","volume":"126","author":"Bailey","year":"2013","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2013.06.010_bib45","unstructured":"Jonas D, Van Scoyoc E, Gerrald K, et\u00a0al. Drug class review: newer diabetes medications, TZDs, and combinations: final original report. Portland, OR: Oregon Health & Science University; 2011. Available at: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK54209\/. Accessed April 22, 2013."},{"key":"10.1016\/j.amjmed.2013.06.010_bib46","unstructured":"European Medicines Agency. Press release: June 2011. Available at: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2011\/06\/news_detail_001275.jsp&murl=menus\/news_and_events\/news_and_events.jsp&mid=WC0b01ac058004d5c1. Accessed April 22, 2013."},{"key":"10.1016\/j.amjmed.2013.06.010_bib47","unstructured":"Merck Sharp & Dohme Corp. Januvia prescribing information. Available at: http:\/\/www.merck.com\/product\/usa\/pi_circulars\/j\/januvia\/januvia_pi.pdf. Accessed April 22, 2013."},{"key":"10.1016\/j.amjmed.2013.06.010_bib48","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1463-1326.2010.01351.x","article-title":"Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial","volume":"13","author":"Hollander","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.amjmed.2013.06.010_bib49","doi-asserted-by":"crossref","first-page":"103","DOI":"10.7326\/0003-4819-154-2-201101180-00300","article-title":"Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial","volume":"154","author":"Buse","year":"2011","journal-title":"Ann Intern Med"},{"issue":"Suppl 1","key":"10.1016\/j.amjmed.2013.06.010_bib50","first-page":"S37","article-title":"Adding insulin detemir (IDet) to liraglutide and metformin improves glycaemic control with sustained weight reduction and low hypoglycaemia rate: 52 week results","volume":"54","author":"Bain","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.amjmed.2013.06.010_bib51","unstructured":"Amylin Pharmaceuticals, Inc. Byetta\u00ae (exenatide) package insert. October 2011. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021773s029s030lbl.pdf. Accessed April 22, 2013."},{"key":"10.1016\/j.amjmed.2013.06.010_bib52","unstructured":"Bristol-Myers Squibb\/AstraZeneca. Byetta\u00ae (exenatide) SPC. July 2012. Available at: http:\/\/www.medicines.org.uk\/EMC\/medicine\/19257\/SPC\/Byetta+5+micrograms+solution+for+injection%2c+prefilled+pen.++Byetta+10+micrograms+solution+for+injection%2c+prefilled+pen.\/. Accessed April 22, 2013."},{"key":"10.1016\/j.amjmed.2013.06.010_bib53","unstructured":"Novo Nordisk A\/S. Levemir\u00ae (insulin detemir) SPC. November 2011. Available at: http:\/\/www.medicines.org.uk\/EMC\/medicine\/14584\/SPC\/Levemir++Cartridge+100+U+ml+-+Penfill%2c++Levemir+Pre-filled+Pen+100+U+ml+-+FlexPen+and+InnoLet\/. Accessed April 22, 2013."},{"key":"10.1016\/j.amjmed.2013.06.010_bib54","unstructured":"Novo Nordisk, Inc. Levemir\u00ae (insulin detemir) package insert. May 2011. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021536s041lbl.pdf. Accessed April 22, 2013."}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934313004889?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934313004889?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:01:03Z","timestamp":1757581263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934313004889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":54,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0002934313004889"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2013.06.010","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Initiating Basal Insulin Therapy in Type 2 Diabetes: Practical Steps to Optimize Glycemic Control","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2013.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}